EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Melanoma antigens recognized by T cells and their use for immunotherapy

Shigeki Ohta, Aya Misawa, Chaw Kyi-Tha-Thu, Naomi Matsumoto, Yoshie Hirose, Yutaka Kawakami iD

Experimental Dermatology · 2023

DOI: 10.1111/exd.14741 ↗

At a glance

Übersichtsarbeit in Experimental Dermatology, 2023. Written by Shigeki Ohta and 5 co-authors. Institution: Department of Immunology, School of Medicine, International University of Health and Welfare, Chiba, Japan. Major MEDLINE topics: Melanoma, Cancer Vaccines. Cited 15 times so far (Crossref); 91 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Japan Agency for Medical Research and Development, Ministry of Education, Culture, Sports, Science and Technology.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Melanoma has been a prototype for cancer immunology research, and the mechanisms of anti‐tumor T‐cell responses have been extensively investigated in patients treated with various immunotherapies. Individual differences in cancer‐immune status are defined mainly by cancer cell characteristics such as DNA mutations generating immunogenic neo‐antigens, and oncogene activation causing immunosuppression, but also by patients' genetic backgrounds such as HLA types and genetic polymorphisms of immune related molecules, and environmental and lifestyle factors such as UV rays, smoking, gut microbiota and concomitant medications; these factors have an influence on the efficacy of immunotherapy. Recent comparative studies on responders and non‐responders in immune‐checkpoint inhibitor therapy using various new technologies including multi‐omics analyses on genomic DNA, mRNA, metabolites and microbiota and single cell analyses of various immune cells have led to the advance of human tumor immunology and the development of new immunotherapy. Based on the new findings from these investigations, personalized cancer immunotherapies along with appropriate biomarkers and therapeutic targets are being developed for patients with melanoma. Here, we will discuss one of the essential subjects in tumor immunology: identification of immunogenic tumor antigens and their effective use in various immunotherapies including cancer vaccines and adoptive T‐cell therapy.

Subjects

MeSH terms (MEDLINE)

MelanomaCancer VaccinesHumansT-LymphocytesMelanoma-Specific AntigensImmunotherapyAntigens, NeoplasmImmunotherapy, Adoptive

Author keywords

adoptive cell therapycancer immunotherapyimmune-checkpoint inhibitormelanoma antigensneo-antigensvaccine

Substances

Melanoma-Specific AntigensAntigens, NeoplasmCancer Vaccines

Authors and institutions

  • Department of Immunology, School of Medicine, International University of Health and Welfare, Chiba, Japan.
  • Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.

ORCID profiles: Yutaka Kawakami

Funding

  • Japan Agency for Medical Research and Development
  • Ministry of Education, Culture, Sports, Science and Technology

Cite

APA

Ohta, S., Misawa, A., Kyi-Tha-Thu, C., Matsumoto, N., Hirose, Y., & Kawakami, Y. (2023). Melanoma antigens recognized by T cells and their use for immunotherapy. Experimental Dermatology. https://doi.org/10.1111/exd.14741

Vancouver

Ohta S, Misawa A, Kyi-Tha-Thu C, Matsumoto N, Hirose Y, Kawakami Y. Melanoma antigens recognized by T cells and their use for immunotherapy. Experimental Dermatology. 2023. doi:10.1111/exd.14741

BibTeX
@article{Ohta2023,
  author = {Ohta, Shigeki and Misawa, Aya and Kyi-Tha-Thu, Chaw and Matsumoto, Naomi and Hirose, Yoshie and Kawakami, Yutaka},
  title = {Melanoma antigens recognized by T cells and their use for immunotherapy},
  journal = {Experimental Dermatology},
  year = {2023},
  doi = {10.1111/exd.14741}
}
Start for free →